Karen Wagner

Biography

Dr. Karen Wagner, Ph.D. is a General Partner of Ysios Capital Partners, SGEIC, S.A.U. Dr. Wagner was a Venture Partner of Ysios Capital Partners, SGEIC, S.A.U. She focuses on therapeutic investments and on the identification and evaluation of investment opportunities. She works with several biotechnology companies as an independent Consultant in business development and licensing besides her professional relationship with Ysios. Prior to this, she served as a Global Alliance Director of F. Hoffmann-La Roche, with responsibility to secure for F. Hoffmann's Global Research Function a number of key technologies for drug discovery as well as compounds for treatment of oncological and viral diseases. From 2007 to 2014, she managed an independent consultancy firm providing advice and hands-on support to various biotechnology companies in business development and strategy. Dr. Wagner served as a Project Leader of the Alnylam-Roche collaboration. She joined Alnylam-Roche from GLYCART. Dr. Wagner was responsible for business development, negotiating key in- and out-licensing agreements and alliance management in the areas of drug discovery technologies, preclinical oncology and viral diseases. From 2001 to 2004, she served as a Business Development Director of Ingenium Pharmaceuticals. Previously, she served as a Consultant and Member of McKinsey & Company's Global Healthcare Practice. She serves as the Chairman of AELIX Therapeutics SL. She serves as a Director of Ysios Capital Partners, SGEIC, S.A.U. She has been a Director of Aelix Therapeutics SL since January 11, 2016. She serves as Director of Minoryx Therapeutics and Vivet Therapeutics. She served as a Director of Kala Pharmaceuticals, Inc. She served as a Director of Cardoz AB. Dr. Wagner holds a Ph.D. in Cell Biology and a Master's Degree in Molecular Biology from the University of Konstanz in Germany.

Research Interest

Business Management